Nothing Special   »   [go: up one dir, main page]

ATE210643T1 - Prostaglandin-analoga zur behandlung von osteoporose - Google Patents

Prostaglandin-analoga zur behandlung von osteoporose

Info

Publication number
ATE210643T1
ATE210643T1 AT93921469T AT93921469T ATE210643T1 AT E210643 T1 ATE210643 T1 AT E210643T1 AT 93921469 T AT93921469 T AT 93921469T AT 93921469 T AT93921469 T AT 93921469T AT E210643 T1 ATE210643 T1 AT E210643T1
Authority
AT
Austria
Prior art keywords
osteoporosis
treatment
prostaglandins
compounds
prostaglandin analogues
Prior art date
Application number
AT93921469T
Other languages
English (en)
Inventor
Peter C Tyler
Robert N Young
Gideon A Rodan
Rejean Ruel
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE210643T1 publication Critical patent/ATE210643T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3873Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT93921469T 1992-09-11 1993-09-09 Prostaglandin-analoga zur behandlung von osteoporose ATE210643T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/944,149 US5409911A (en) 1992-09-11 1992-09-11 Prostaglandin analog for treating osteoporosis
PCT/US1993/008529 WO1994006750A1 (en) 1992-09-11 1993-09-09 Prostaglandin analog for treating osteoporosis

Publications (1)

Publication Number Publication Date
ATE210643T1 true ATE210643T1 (de) 2001-12-15

Family

ID=25480889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921469T ATE210643T1 (de) 1992-09-11 1993-09-09 Prostaglandin-analoga zur behandlung von osteoporose

Country Status (9)

Country Link
US (1) US5409911A (de)
EP (1) EP0662075B1 (de)
JP (1) JPH08501546A (de)
AT (1) ATE210643T1 (de)
AU (1) AU677597B2 (de)
CA (1) CA2144093A1 (de)
DE (1) DE69331326T2 (de)
ES (1) ES2169046T3 (de)
WO (1) WO1994006750A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914099A (en) * 1995-05-12 1999-06-22 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
WO1996039107A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
JPH11506757A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 二ナトリウムアレンドロネート製剤
US6303155B1 (en) 1996-02-15 2001-10-16 Hadasit Medical Research Services And Development Company, Ltd. Treatment of conditions associated with impairment in the level of the parathyroid hormone
US5935607A (en) * 1996-02-15 1999-08-10 Hadasit Medical Research Services And Development Company Ltd. Treatment of osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AU4881697A (en) 1996-12-20 1998-07-17 Pfizer Inc. Prevention and treatment of skeletal disorder with EP2 receptor subtype se lective prostaglandin E2 agonists
AU731153B2 (en) * 1997-09-09 2001-03-22 Duke University Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists
IL134760A0 (en) * 1997-09-09 2001-04-30 Procter & Gamble Method of increasing bone volume using non-naturally-occurring fp selective agonists
ID24845A (id) * 1997-09-09 2000-08-24 Procter & Gamble Prostaglandin tetrahidro tersubstitusi c16-c20 aromatik yang berguna sebagai agonis fp
CA2338000C (en) * 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble 4-thio-maleimido derivatives and methods for their production
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
EP1158987A1 (de) * 1999-03-05 2001-12-05 The Procter & Gamble Company Verfahren zur erhohung des knochenvolumens mittels nicht natürlich vorkommenden fp agonisten und antiresorptiva
MXPA01011227A (es) 1999-05-04 2002-07-02 Strakan Ltd Glicosidas androgenas y su actividad androgenica.
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
DE60003435T2 (de) * 1999-08-04 2004-05-19 The Procter & Gamble Company, Cincinnati Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
EP1267888A4 (de) 2000-01-04 2005-12-28 Univ California Verwendung von niedrigdosierten bisphosphonaten zur verhinderung der verkalkung von herz und arterien
WO2001051497A1 (en) * 2000-01-14 2001-07-19 Strakan Limited Novel bisphosphonates and uses thereof
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
CN100463910C (zh) * 2006-12-14 2009-02-25 西北工业大学 二膦酸盐衍生物的制备方法
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CA2738045C (en) * 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
WO2012113571A1 (en) 2011-02-24 2012-08-30 Ktb Tumorforschungsgesellschaft Mbh Bisphosphonate-prodrugs
CN106316910A (zh) 2011-06-02 2017-01-11 奇诺因私人有限公司 用于制备前列腺素酰胺的新的方法
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
EP3307747A4 (de) 2015-06-12 2019-02-27 Simon Fraser University Amid-verlinkte ep4-agonist-bisphosphonatverbindungen und verwendungen davon
WO2017152044A1 (en) 2016-03-04 2017-09-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975404A (en) * 1971-05-04 1976-08-17 The Upjohn Company Bicyclic lactone intermediates
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US4018892A (en) * 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
ATE66608T1 (de) * 1984-04-30 1991-09-15 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
JPS6191137A (ja) * 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
DE3519361A1 (de) * 1985-05-30 1986-12-04 Boehringer Ingelheim International GmbH, 6507 Ingelheim (gamma)-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
EP0341961A3 (de) * 1988-05-09 1990-06-20 Merck & Co. Inc. Polymalonsäuren als Knochenaffinitätsagent
JPH0778024B2 (ja) * 1988-10-14 1995-08-23 藤沢薬品工業株式会社 医薬化合物とジホスホン酸誘導体の結合体を含有する医薬用製剤
JPH0759505B2 (ja) * 1988-11-17 1995-06-28 帝人株式会社 シクロペンテノン類を活性成分とする骨形成促進剤
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
EP0496520A1 (de) * 1991-01-22 1992-07-29 Merck & Co. Inc. Knochenaktive Verbindungen
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation

Also Published As

Publication number Publication date
EP0662075B1 (de) 2001-12-12
ES2169046T3 (es) 2002-07-01
DE69331326T2 (de) 2002-11-07
EP0662075A4 (de) 1998-05-20
CA2144093A1 (en) 1994-03-31
WO1994006750A1 (en) 1994-03-31
JPH08501546A (ja) 1996-02-20
AU677597B2 (en) 1997-05-01
US5409911A (en) 1995-04-25
AU4855493A (en) 1994-04-12
DE69331326D1 (de) 2002-01-24
EP0662075A1 (de) 1995-07-12

Similar Documents

Publication Publication Date Title
ATE210643T1 (de) Prostaglandin-analoga zur behandlung von osteoporose
IL104109A (en) Pharmaceutical compositions containing aldenorate for treating periodontal diseases
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
DE60211935D1 (de) Alkandiol derivate zur behandlung von knochenkrankheiten
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
GR3033127T3 (en) Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
ATE417615T1 (de) Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen
EE9600191A (et) Püridüülbisfosfonaatide kasutamine terapeutiliste toimeainetena
SE8903529D0 (sv) Medical use
DE60212621D1 (de) Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis
KR970705400A (ko) 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
DE69206607D1 (de) Behandlung von kognitiven störungen.
DE50108711D1 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
ATE172118T1 (de) Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose
DE60108775T8 (de) Methode zur behandlung von schlaganfall
MX9606180A (es) Piridilbisfosfonatos para utilizarse como un agente terapeutico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties